Imatinib Ratiopharm (Imatinib Mesilate)

Imatinib Ratiopharm is a tyrosine kinase inhibitor used in hematologic and solid‑tumor malignancies driven by specific genetic abnormalities.

• Chronic myeloid leukemia (CML): reduces leukemic cell proliferation and induces cytogenetic remission.
• Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): achieves disease control and improves overall survival.
• Gastrointestinal stromal tumor (GIST): inhibits tumor growth in patients with KIT or PDGFRA mutations.

• Imatinib Mesilate selectively binds to the ATP‑binding pocket of the BCR‑ABL, KIT and PDGFRA tyrosine kinases, stabilising them in an inactive conformation. By competitively blocking ATP access, it prevents phosphorylation of downstream substrates, halting proliferative signalling pathways and inducing apoptosis of malignant cells that rely on these kinases.

Imatinib Ratiopharm may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Edema: peripheral fluid retention.
• Muscle cramps or pain.
• Fatigue or weakness.

Serious or Rare Side Effects

• Neutropenia: marked decrease in white blood cells.
• Hepatotoxicity: elevated liver enzymes or hepatitis.
• Cardiac failure: reduced left‑ventricular function.
• Pulmonary arterial hypertension: rare increase in pulmonary arterial pressure.

When prescribing Imatinib Ratiopharm, clinicians should consider several precautionary measures to ensure patient safety.

• Monitor blood counts: regular CBC to detect cytopenias.
• Assess liver function: periodic LFTs for hepatotoxicity.
• Evaluate cardiac status: baseline and periodic echocardiograms in at‑risk patients.
• Check for drug interactions: avoid concomitant strong CYP3A4 inhibitors when possible.
• Pregnancy and lactation: avoid use unless benefits outweigh risks; discuss with specialist.
• Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Imatinib Ratiopharm can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase imatinib exposure and toxicity.
• Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce plasma levels and effectiveness.
• Antacids containing aluminum or magnesium: can decrease absorption if taken simultaneously.

Moderate Interactions (Monitor Closely)

• Acid‑reducing agents (e.g., proton pump inhibitors): may modestly lower bioavailability.
• Warfarin: may enhance anticoagulant effect; monitor INR.
• Live attenuated vaccines: potential reduced efficacy; consider timing of administration.